Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Immunogen Inc
(NQ:
IMGN
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Feb 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
31.23 (2,500)
Ask (Size)
31.25 (400)
Prev. Close
31.25
Today's Range
N/A - N/A
52wk Range
12.43 - 31.24
Shares Outstanding
266,264,274
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
3 Unstoppable Mega-Cap Stocks That Every Investor Should Own in 2024
March 09, 2024
Dive into the world of three unstoppable mega-cap stocks leading the charge amidst the bullishness in the market.
Via
InvestorPlace
Amicus Therapeutics Stock Sees Improved Relative Strength Rating
February 09, 2024
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 64 to 78 on Friday.
Via
Investor's Business Daily
Performance
More News
Read More
ImmunoGen Inc. (NASDAQ: IMGN) Near Top of Volume Charts in Thursday Trading
February 08, 2024
Via
Investor Brand Network
3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List
February 06, 2024
Via
InvestorPlace
7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024
February 06, 2024
Via
InvestorPlace
Madrigal Pharmaceuticals Stock Shows Rising Relative Strength
February 06, 2024
Via
Investor's Business Daily
AbbVie Lifts Long-Term Outlook For New Immunology Drugs, Even As Q4 Revenue and Profit Fall
February 02, 2024
Via
Benzinga
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 01, 2024
From
ImmunoGen, Inc.
Via
Business Wire
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
January 29, 2024
Via
Get News
Exposures
Product Safety
AbbVie's Transformational 2023, Analyst Anticipates Growth in 2024 Amid Competitive Pressures
January 29, 2024
Via
Benzinga
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
January 29, 2024
Via
News Direct
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
January 29, 2024
Via
TheNewswire.com
Exposures
Product Safety
ABBV: This Top Biotech Just Went On A Buying Spree
January 25, 2024
Via
Talk Markets
Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating
January 23, 2024
Via
Investor's Business Daily
7 Dividend Aristocrats That Will Pay You for Years to Come
January 22, 2024
Via
InvestorPlace
Ultragenyx Pharm Stock Earns IBD Stock Upgrade With RS Rating Jump To 83
January 18, 2024
Via
Investor's Business Daily
Cassava Sciences Stock Continues Showing Rising Relative Strength
January 16, 2024
Via
Investor's Business Daily
Cramer Says This Major Healthcare Stock Is 'Ridiculously Cheap And Doing So Many Great Things'
January 08, 2024
Via
Benzinga
Is AbbVie Stock a Buy Now?
January 07, 2024
Via
The Motley Fool
Topics
Intellectual Property
Exposures
Intellectual Property
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Via
Investor's Business Daily
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 03, 2024
From
ImmunoGen, Inc.
Via
Business Wire
3 Biotech Stocks Set for Breakthroughs in 2024
January 02, 2024
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
January 02, 2024
Via
Benzinga
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
December 29, 2023
Via
MarketBeat
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
December 29, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.